Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion.

As pituitary leukemia-inhibitory factor (LIF) mediates neuroimmune signals to the hypothalamo-pituitary-adrenal axis, we tested the role of intracellular SOCS-3 in corticotroph function. SOCS-3, a cytokine-inducible protein of the suppressor of cytokine signaling (SOCS) family, is expressed in the murine pituitary in vivo. After i.p. injection of LIF (5.0 micrograms/mouse) or interleukin-1 beta (0.1 microgram/mouse) pituitary SOCS-3 mRNA was stimulated 9-fold and 6-fold, respectively. Also, in corticotroph AtT-20 cells LIF and interleukin-1 beta both potently stimulated SOCS-3 mRNA expression. In AtT-20 cells, stable overexpression of SOCS-3 inhibits basal and LIF-stimulated ACTH secretion in comparison to mock-transfected AtT-20 cells (basal: 4426 +/- 118 vs. 4973 +/- 138 pg/ml, P < 0.05; LIF-induced: 5511 +/- 172 vs. 9308 +/- 465 pg/ml, P < 0.001). Stable overexpression of SOCS-3 cDNA in AtT-20 cells also resulted in a significant 50% decrease of LIF-induced POMC mRNA levels (P < 0.05) and POMC promoter activity (P < 0.001), respectively. Western blot analysis revealed an inhibition of LIF-stimulated gp130 and STAT-3 phosphorylation in SOCS-3 overexpressing AtT-20 cells. Thus, SOCS-3 inhibits the Janus kinase (JAK) and signal transducers and activators of transcription (STAT) pathway, which is known to mediate LIF-stimulated ACTH secretion and POMC gene expression. In conclusion, SOCS-3 functions as an intracellular regulator of POMC gene expression and ACTH secretion, acting as a negative feedback mediator of the cytokine-mediated neuro-immuno-endocrine interface.

[1]  S. Melmed,et al.  Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. , 1998, Endocrinology.

[2]  S. Melmed,et al.  Leukemia Inhibitory Factor Modulates Interleukin-1β-Induced Activation of the Hypothalamo-Pituitary-Adrenal Axis. , 1998, Endocrinology.

[3]  N. Vaysse,et al.  sst2 Somatostatin Receptor Mediates Negative Regulation of Insulin Receptor Signaling through the Tyrosine Phosphatase SHP-1* , 1998, The Journal of Biological Chemistry.

[4]  U. Ikeda,et al.  SOCS-1/JAB/SSI-1 Can Bind to and Suppress Tec Protein-tyrosine Kinase* , 1997, The Journal of Biological Chemistry.

[5]  H. Sakamoto,et al.  Cloning and characterization of novel CIS family genes. , 1997, Biochemical and biophysical research communications.

[6]  W. Banks,et al.  Relative contributions of peripheral and central sources to levels of IL-1α in the cerebral cortex of mice: assessment with species-specific enzyme immunoassays , 1997, Journal of Neuroimmunology.

[7]  T. Naka,et al.  Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. , 1997, Biochemical and biophysical research communications.

[8]  D. Ray,et al.  Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. , 1997, The Journal of clinical investigation.

[9]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[10]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[11]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[12]  A. Yoshimura,et al.  CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. , 1997, Blood.

[13]  D. Ray,et al.  A Common Pro-opiomelanocortin-binding Element Mediates Leukemia Inhibitory Factor and Corticotropin-releasing Hormone Transcriptional Synergy* , 1997, The Journal of Biological Chemistry.

[14]  D. Ray,et al.  Pituitary cytokine and growth factor expression and action. , 1997, Endocrine reviews.

[15]  J. Licinio,et al.  Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Melmed,et al.  Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. , 1996, Endocrinology.

[17]  D. Ray,et al.  Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. , 1996, The Journal of clinical investigation.

[18]  N. Copeland,et al.  A novel cytokine‐inducible gene CIS encodes an SH2‐containing protein that binds to tyrosine‐phosphorylated interleukin 3 and erythropoietin receptors. , 1995, The EMBO journal.

[19]  G. Chrousos,et al.  The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.

[20]  S. Melmed,et al.  Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. , 1995, The Journal of clinical investigation.

[21]  P. Patterson,et al.  Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Orth.  Corticotropin-releasing hormone in humans. , 1992, Endocrine reviews.

[23]  Comeau,et al.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. , 1992, Science.

[24]  D. Hilton,et al.  Purification of a murine leukemia inhibitory factor from Krebs ascites cells. , 1988, Analytical biochemistry.